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Abstract
Background: HLA class I genotype is a major determinant of the outcome of HIV infection, and the impact of certain alleles
on HIV disease outcome is well studied. Recent studies have demonstrated that certain HLA class I alleles that are in linkage
disequilibrium, such as HLA-A*74 and HLA-B*57, appear to function co-operatively to result in greater immune control of
HIV than mediated by either single allele alone. We here investigate the extent to which HLA alleles - irrespective of linkage
disequilibrium - function co-operatively.
Methodology/Principal Findings: We here refined a computational approach to the analysis of .2000 subjects infected
with C-clade HIV first to discern the individual effect of each allele on disease control, and second to identify pairs of alleles
that mediate ‘co-operative additive’ effects, either to improve disease suppression or to contribute to immunological failure.
We identified six pairs of HLA class I alleles that have a co-operative additive effect in mediating HIV disease control and four
hazardous pairs of alleles that, occurring together, are predictive of worse disease outcomes (q,0.05 in each case). We
developed a novel ‘sharing score’ to quantify the breadth of CD8+ T cell responses made by pairs of HLA alleles across the
HIV proteome, and used this to demonstrate that successful viraemic suppression correlates with breadth of unique CD8+ T
cell responses (p=0.03).
Conclusions/Significance: These results identify co-operative effects between HLA Class I alleles in the control of HIV-1 in an
extended Southern African cohort, and underline complementarity and breadth of the CD8+ T cell targeting as one
potential mechanism for this effect.
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Introduction
CD8+ T cells are a key component of the adaptive immune
response to HIV-1, both in acute [1,2] and chronic [3,4] infection.
This response is directed by the presentation of HIV-1 epitopes on
the surface of infected cells by host HLA Class I molecules. The
HLA-B locus is the strongest genetic determinant of disease
outcome [5,6], but beneficial effects of certain HLA-A [7,8] and
HLA-Cw [6,9,10] alleles have also been reported. Although a
small number of disease-protective and disease-susceptible alleles
have been well characterised, ascertaining the impact of many
alleles can be difficult due to factors including low phenotypic
frequency, linkage disequilibria between alleles, and small effects
on disease outcome.
Based on these observations, and the known benefits of HLA
Class I heterozygosity in mediating virologic control [11], we have
recently investigated the potential for a co-operative additive effect
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e47799between HLA alleles in suppressing viraemia, and demonstrated
that certain combinations of alleles can work in tandem to mediate
HIV-1 disease control [7,12]. This effect is exemplified by HLA-
A*74 and HLA-B*57 [7], alleles that occur in linkage disequilib-
rium in some Southern African populations, making the role of
each individual allele on disease control potentially difficult to
ascertain.
Larger cohorts allow for more refined analysis, enabling us to
demonstrate that when each of two alleles independently exert a
favourable impact, their co-occurrence may additionally have a
combined effect. The test we have used here measures an effect
where having two alleles working together additively has more
impact on outcome (e.g. viral load or CD4+ T cell count) than
having either one of them alone. This contrasts with a standard
additive test which tests whether one allele has an additive effect
above and beyond that of another. In the case where the first allele
has little effect and the second allele a substantial effect, testing the
two alleles against the first with a standard additive test would yield
a positive result, whereas it would not with our test. We refer to the
effect measured by our new test as a ‘co-operative additive effect’.
The mechanism behind such effects is not clearly understood, but
we have previously hypothesized that the reason for a combined
benefit of HLA-A*74 and HLA-B*57 is – at least in part - the
expanded repertoire of unique and complementary CD8+ T cell
epitopes presented by the two alleles in combination [7].
We here built upon our previous methods [7] to further develop
an extended systematic approach studying an enlarged Southern
African cohort (Table 1). This aims to identify, first, the
contribution of individual alleles to HIV-1 disease control, and
second, any potential co-operative additive effects between pairs of
HLA Class I alleles. We have generalized our previous method so
as to allow identification of these effects irrespective of locus and
linkage disequilibrium. We also sought to explore the hypothesis
that these co-operative additive effects are accounted for by the
enhanced breadth of CD8+ T cell epitopes presented by pairs of
co-operative alleles, developing a new ‘sharing score’ to quantify
breadth of unique CD8+ T cell responses, and demonstrating a
correlation between breadth of responses and viraemic control.
Results
Univariate analysis confirms individual alleles that predict
HIV-1 disease control or progression
We first sought to identify single HLA alleles that are predictive
of better or worse disease outcome with respect to viral load and
CD4+ T cell count in our cohort of 2031 Southern African adult
subjects with C-clade HIV-1 infection. Using the more stringent
cut-off of q,0.05 (FDR 5% [13]), we identified nine HLA alleles
significantly associated with viraemic suppression (highlighted in
Table 2, upper panel), and ten alleles associated with preservation
of CD4+ T cell count (highlighted in Table 3, upper panel),
representing a total of 14 different HLA class I alleles that are of
benefit in disease control in this cohort (q,0.05). Five alleles,
HLA-A*74, -B*57, -B*58:01, -B*81 and –Cw*18 were statistically
associated with both lower viral load and higher CD4+ T cell
count with q,0.05 (upper panels of Tables 2 and 3).
We also identified a total of nine different HLA alleles
associated with a ‘hazardous’ (detrimental) outcome either with
either respect to viraemic control (highlighted in Table 2, lower
panel) and/or CD4+ T cell count (Table 3, lower panel) (q,0.05).
Seven alleles were predictive of worse outcome with respect to
both viral load and CD4+ T cell count: HLA-A*66, -B*08, -B*18,
- B*45, -B*58:02, -Cw*06 and -Cw*16 (with q,0.05; lower panels
of Tables 2 and 3).
Using the less stringent criterion of q,0.2 (FDR 20%), we
identified 17 alleles that are associated with favourable viraemic
control and 13 alleles associated with poor viraemic control
(Table 2). Likewise, for CD4+ T cell count with q,0.2, we
identified 13 alleles associated with good outcome, and 11 alleles
associated with lowered CD4+ T cell counts (Table 3). Many of
these associations between HLA Class I alleles and HIV-1 disease
outcome have previously been reported by ourselves and other
groups studying C-clade infected cohorts [5,7,8,14,15,16]. How-
ever, a previous univariate analysis in 1211 South African subjects
demonstrated fewer alleles that are significantly associated with
viral set-point (in this earlier work, only five such HLA associations
remained significant after correction for multiple comparisons
[12]). All five of these alleles previously reported to be significantly
correlated with steady-state viral load feature again here in the
extended list generated from analysis of an enlarged cohort
(Table 2).
Identification of pairs of HLA alleles that co-operate to
influence HIV-1 disease outcomes
We identified six pairs of protective alleles that have a co-
operative additive effect in mediating disease control (with
q,0.05); these pairs are highlighted in Table 4. Three of these
six HLA pairs that are associated with disease control are in
significant linkage disequilibrium (that is, the two alleles in the pair
are in linkage disequilibrium). Based on the computational method
used, which accounts for linkage disequilibrium, linkage between
alleles does not drive these results. That is, if two alleles are either
in complete linkage, or are never observed together, then our test
yields no statistical power to detect a co-operative additive effect,
because the test needs enough examples of alleles to observe
together, and apart, in order to assess the impact of having both as
compared to just one. That two alleles arise together more
frequently together than expected by chance cannot alone drive
the test statistic. The enhanced size of this current cohort allowed
us to identify many more associations than were previously
Table 1. Characteristics of 2031 Southern African adult subjects with C-Clade HIV-1 infection enrolled in four cohorts.
Cohort Location Number of Subjects Median CD4 (IQR
a), cells/mm
3 Median VL (IQR
a), copies/ml
Bloemfontein, South Africa 261 76 (32-548) 84000 (13000-250000)
Durban, South Africa 1225 376 (239-520) 38200 (7430-154500)
Kimberley, South Africa 31 326 (275-477) 47000 (8800-295000)
Gaborone, Botswana 514 342 (219-476) 19100 (3920-78200)
Total 2031 352 (204-519) 32800 (6565-140454)
aIQR=interquartile range.
doi:10.1371/journal.pone.0047799.t001
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to have a beneficial effect on disease outcome, only the HLA-
A*74/HLA-B*5703 combination was previously noted to impact
favourably on viraemic control [12]. Another two allele pairs that
were earlier reported to mediate a co-operative effect on disease
outcome, HLA-B*81/HLA-Cw*04, and HLA-B*39/HLA-Cw*12
[12], did not reach statistical significance in this current analysis
(i.e q.0.2 in each case).
Using the same approach, we also detected four ‘hazardous’
pairs of alleles with q,0.05 for which the expression of both alleles
predicts worse disease outcome than expression of either one alone
(these pairs are highlighted in Table 5). All pairs of alleles
mediating a significant co-operative additive effect (with the less
stringent FDR of q,0.2) are shown in Table 4 (beneficial pairs)
and Table 5 (hazardous pairs).
Alleles that mediate a co-operative additive effect to
control disease target a greater breadth of the HIV
proteome
We hypothesized that co-operative additive effects in disease
control might hinge on the presentation of combinations of alleles
that present distinct epitopes from each other [9,17,18], as
previously suggested for HLA-A*74 and HLA-B*57 [7]. Using the
approach of calculating a ‘sharing score’ to quantify breadth of
epitope coverage, as described in Materials and Methods, we
demonstrated a significant correlation between the sharing score
and the p-value of an additive effect for VL (R=20.08, p=0.03;
data not shown). The direction of this correlation is in the expected
direction, i.e. the negative R-value demonstrates that a larger
sharing score (reflecting a greater breadth of epitope coverage)
correlates with a smaller p-value (indicative of a stronger co-
operative additive effect between alleles); thus, the greater the
epitope coverage, the more the co-operative effect.
This suggests that some of the co-operative additive effect
mediated by a pair of alleles can be accounted for by an increased
Table 2. Univariate analysis of the impact of HLA Class I
alleles on HIV-1 viral load in 2031 HIV-1 C-clade infected
Southern African subjects (q,0.2).
HLA allele
a
Phenotypic
frequency (%) Weight
b p-value q-value
B*15:01 0.6 0.65 3.01E-02 0.11
B*57 6.2 0.63 8.42E-12 7.24E-10
Cw*12 3.2 0.45 4.48E-04 3.86E-03
A*74 10.2 0.34 1.03E-05 1.88E-04
B*13 2.8 0.32 1.96E-02 8.01E-02
B*39 3.6 0.32 7.44E-03 4.00E-02
Cw*18 11.6 0.29 2.49E-05 3.57E-04
B*81 10.0 0.28 1.60E-04 1.72E-03
B*58:01 10.6 0.26 3.81E-04 3.65E-03
A*33 4.8 0.23 3.12E-02 0.11
B*14 7.1 0.19 3.45E-02 0.12
B*42 22.8 0.18 1.12E-03 8.35E-03
A*01 7.2 0.17 5.23E-02 0.16
Cw*17 24.9 0.15 6.34E-03 3.63E-02
Cw*08 10.9 0.14 6.05E-02 0.16
Cw*04 23.6 0.14 1.33E-02 5.74E-02
B*44 16.6 0.13 3.13E-02 0.11
B*15:10 16.2 -0.11 7.00E-02 0.18
B*15:03 16.9 -0.11 6.01E-02 0.16
Cw*02 21.1 -0.12 3.68E-02 0.12
A*03 11.2 -0.13 6.00E-02 0.16
A*66 8.3 -0.21 9.31E-03 4.45E-02
Cw*16 11.6 -0.21 2.42E-03 1.60E-02
B*08 10.6 -0.23 1.54E-03 1.10E-02
A*68:01 6.4 -0.26 4.24E-03 2.60E-02
B*45 9.6 -0.30 1.42E-04 1.72E-03
Cw*06 29.4 -0.31 4.54E-10 1.30E-08
B*58:02 22.0 -0.35 9.71E-11 4.18E-09
A*80 1.6 -0.35 4.30E-02 0.14
B*18 6.1 -0.42 1.09E-05 1.88E-04
aAlleles in bold and underlined are those that remain significant with a more
stringent FDR of q,0.05.
bAlleles with a positive weight (above double line) are associated with
statistically significant disease control; alleles with a negative weight (below
double line) are associated with hazardous (detrimental) outcome.
doi:10.1371/journal.pone.0047799.t002
Table 3. Univariate analysis of the impact of HLA Class I
alleles on CD4+ T cell count in 2031 HIV-1 C-clade infected
Southern African subjects (q,0.2).
HLA allele
a Phenotypic frequency (%) Weight
b p-value q-value
B*40 0.5 0.28 3.55E-02 0.11
B*57 6.2 0.23 1.21E-08 7.96E-07
A*33 4.8 0.15 8.70E-04 6.38E-03
B*14 7.1 0.13 2.89E-04 3.28E-03
Cw*12 3.2 0.12 2.81E-02 9.28E-02
A*74 10.2 0.11 4.87E-04 4.60E-03
B*81 10.0 0.11 6.91E-04 5.70E-03
B*58:01 10.6 0.10 1.38E-03 7.60E-03
Cw*18 11.6 0.10 1.14E-03 7.49E-03
B*35 4.1 0.09 6.65E-02 0.19
Cw*04 23.6 0.09 6.04E-05 1.33E-03
Cw*08 10.9 0.08 1.04E-02 3.84E-02
B*44 16.6 0.07 4.93E-03 2.17E-02
A*30 36.3 -0.05 1.57E-02 5.44E-02
A*23 18.7 -0.05 4.44E-02 0.13
A*68:01 6.4 -0.07 7.04E-02 0.19
Cw*06 29.4 -0.08 1.70E-04 2.81E-03
A*66 8.3 -0.09 7.74E-03 3.01E-02
B*45 9.6 -0.10 4.00E-03 1.88E-02
B*08 10.6 -0.10 1.33E-03 7.59E-03
B*18 6.1 -0.11 5.59E-03 2.31E-02
Cw*16 11.7 -0.11 2.99E-04 3.28E-03
B*58:02 22.0 -0.12 9.20E-08 3.04E-06
B*41 1.9 -0.22 2.05E-03 1.04E-02
aAlleles in bold and underlined are those that remain significant with a more
stringent FDR of q,0.05.
bAlleles with a positive weight (above double line) are associated with
statistically significant disease control; alleles with a negative weight (below
double line) are associated with hazardous (detrimental) outcome.
doi:10.1371/journal.pone.0047799.t003
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control, with respect to maintenance of CD4+ T cell count and/or viral load suppression (q,0.2).
HLA-1
a HLA-2 Frequency of pair (%) Linkage
b(p-value) Weight of pair p-value for pair q-value for pair
A*01 B*58:01 0.6 N/S 1.18 2.40E-03 1.91E-01
Cw*08 Cw*18 0.9 N/A 1.03 3.12E-03 1.98E-01
A*02 B*81 1.5 N/S 0.87 2.00E-05 2.97E-03
B*44 Cw*04 8.2 6.95E-33 0.84 2.00E-05 2.97E-03
A*74 B*57 1.5 1.75E-05 0.83 2.00E-05 3.71E-03
A*02 B*44 3.2 N/S 0.70 2.58E-03 1.91E-01
A*74 B*81 1.0 N/S 0.59 2.00E-05 3.71E-03
B*42 B*44 2.2 N/A 0.32 2.46E-03 1.76E-01
B*44 Cw*17 2.6 1.56E-05 0.28 2.74E-03 1.76E-01
B*14 B*81 0.6 N/A 0.25 8.20E-04 9.46E-02
B*14 Cw*18 0.4 N/S 0.24 4.20E-04 6.23E-02
B*58:01 B*81 0.8 N/A 0.21 2.00E-05 4.95E-03
B*58:01 Cw*04 1.2 9.33E-06 0.21 2.00E-05 4.95E-03
B*44 Cw*12 0.3 N/S 0.20 9.60E-04 9.46E-02
B*81 Cw*08 1.3 N/S 0.18 5.32E-03 2.00E-01
B*44 Cw*18 1.1 N/S 0.18 3.88E-03 2.00E-01
A*02 Cw*18 1.7 N/S 0.13 2.92E-03 1.97E-01
A*26 A*34 0.3 N/A 0.09 1.32E-03 1.09E-01
aPairs in bold and underlined are those that remain significant with a more stringent q,0.05.
bLinkage is reported if relevant; otherwise designated as N/S=not significant (corrected for multiple comparisons; only values p,1.9E-05 are reported), or N/A=not
applicable (two alleles at same locus).
doi:10.1371/journal.pone.0047799.t004
Table 5. Multivariate analysis of pairs of HLA Class I alleles, showing pairs associated with hazardous (detrimental) impact on HIV-1
disease control with respect to decline in CD4+ T cell count and/or increased viral load (q,0.2).
HLA-1
a HLA-2 Frequency of pair (%) Linkage
b (p-value) Weight of pair p-value for pair q-value for pair
B*58:02 Cw*16 1.4 N/S 21.17 2.00E-05 2.97E-03
B*45 B*58:02 1.3 N/A 21.03 6.80E-04 7.21E-02
Cw*06 Cw*16 1.9 N/A 20.93 2.00E-05 2.97E-03
Cw*02 Cw*06 3.7 N/A 20.71 1.12E-03 1.04E-01
B*45 B*58:02 1.3 N/A 20.68 2.60E-04 1.98E-01
B*18 Cw*16 0.5 N/S 20.66 1.30E-03 1.38E-01
B*45 Cw*06 3.2 N/S 20.57 2.84E-03 1.76E-01
A*68:01 Cw*02 1.3 N/S 20.37 2.48E-03 1.76E-01
A*68:01 B*15:03 1.1 N/S 20.37 2.58E-03 1.76E-01
A*23 B*41 0.6 N/S 20.26 5.90E-03 2.00E-01
A*23 B*15:03 4.0 N/S 20.23 4.00E-03 1.98E-01
B*08 B*18 0.4 N/A 20.21 2.00E-05 4.95E-03
B*18 B*45 0.4 N/A 20.21 1.24E-03 4.82E-02
B*15:10 B*58:02 2.4 N/A 20.17 4.30E-03 2.00E-01
A*66 Cw*06 5.2 9.15E-22 20.13 4.36E-03 2.00E-01
A*30 A*68:01 1.1 N/A 20.13 5.12E-03 2.00E-01
B*15:10 Cw*06 3.0 4.02E-07 20.13 3.82E-03 2.00E-01
aPairs in bold and underlined are those that remain significant with a more stringent q,0.05.
bLinkage is reported if relevant; otherwise designated as N/S=not significant (corrected for multiple comparisons; only values p,1.9E-05 are reported), or N/A=not
applicable (two alleles at same locus).
doi:10.1371/journal.pone.0047799.t005
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alone. The effect was in the same direction (that is, a direction in
which less sharing is correlated with being more co-operative, as
expected), but not statistically significant, for CD4+ T cell count
(R=20.05, NS; data not shown).
Discussion
These studies provide a useful resource in identifying HLA
Class I alleles that mediate a co-operative additive effect in control
of HIV-1 in C-clade infected African cohorts. The extended size of
this cohort (.2000 individuals) and adaptation of methodology to
identify co-operative additive effects has allowed us to build on
previous analyses [7,12] and to identify the impact of individual or
paired HLA alleles with greater sensitivity. Importantly, however,
in spite of this large cohort size, the analysis remains underpow-
ered given the large number of HLA-pairs and the necessity of a
multiple testing correction. These results are therefore likely an
underestimate of the true extent of HLA co-operativity, and future
studies employing more individuals, or a more restricted set of
tests, are likely to reveal further instances of HLA co-operativity.
Furthermore, our approach of using most HLA data at two-digit
resolution was aimed to maximize statistical power to detect Class
I influences on disease control. However, a caveat of this approach
is that it limits the detection of possible differences occurring at
high-resolution (often a micropolymorphism) level [19]; this could
be addressed in future by use of larger cohorts.
Effects on disease control were not always seen for both CD4
count and VL. Reasons for this likely include imperfect correlation
between CD4 count and VL (r
2=0.22, p,0.0001 by linear
regression; data not shown), and that the linear models are only
idealizations.
Our analysis supports previous evidence that even highly
beneficial responses, such as that restricted by HLA-B*57, can
be improved upon by addition of other T cell responses [7,12].
The mechanism of this phenomenon has not previously been
clearly characterised, but we have here demonstrated that – at
least in part - the effect may be explained by the targeting of non-
overlapping CD8+ T cell epitopes across the HIV proteome.
The correlation between our ‘sharing score’ (reflecting breadth
of epitopes targeted by a pair of alleles) and the probability of a co-
operative additive effect mediated by these alleles was only weak
(R=20.08). Any computational method to assess breadth of
epitope targeting is a challenge, especially given the density of
overlapping CD8+ T cell epitopes in certain regions of the HIV
proteome, the bias towards restricting highly targeted epitopes
restricted by prevalent Class I alleles, and the complexity of
immunodominance patterns. In addition, any single pair of alleles
will also be impacted by the other four HLA Class I molecules
expressed by a given individual, and the overall disease outcome
will be influenced by many factors in addition to HLA genotype.
Furthermore, there is no obvious effect size obtainable for the co-
operative additive test, and even if there were it would be possible
to have large effects for pairs which were not statistically
significant. For these two reasons, we chose to measure correlation
with the p-value from our test.
These difficulties notwithstanding, these data nevertheless do
highlight that two alleles which present different epitopes can each
confer a separate benefit (or hazard) to the individual; thus having
both of them is better (or worse) than having just one of them and
a co-operative additive effect is at play. However, if two alleles
present many of the same epitopes (as exemplified by HLA-B*57
and -B*58:01, or HLA-B*42 and -B*81), they are less likely to act
together co-operatively – having one of them may be little different
from having both. This effect is also underscored by the
phenomenon of heterozygote advantage [11], which may be
mediated by increased breadth of epitopes presented by HLA class
I heterozygotes compared to homozygotes.
As HLA-peptide complexes are ligands not only for T-cell
receptors on CD8+ T cells, but also for KIR receptors on NK cells
[20,21], another potential reason for the favourable (or hazardous)
interaction of some pairs of HLA alleles is the combined effect of a
CD8+ T cell response and an NK-cell response. Homozygosity for
KIR ligands may also explain poor disease outcomes in subjects
with certain HLA Class I combinations, although many of our
pairs involved at least one allele that is not a known KIR ligand.
Characterising interplay between HLA alleles is made difficult
by the presence of linkage disequilibrium between alleles.
However, our test statistic will not be significant for two alleles
simply because they are in linkage disequilibrium, but rather the
test can find two alleles to have a co-operative additive effect despite
their being in (incomplete) linkage disequilibrium, albeit with
reduced power owing to fewer observations of the alleles acting
one without the other. That is, if one observes each allele only in
the context of the other, or never together, it is impossible to
determine whether nor not they have a co-operative additive effect
(hence these pairs removed from analysis; see Methods section).
However, because one needs to observe enough co-occurrences of
the alleles, having alleles in incomplete linkage disequilibrium
increases the power to detect co-operative additive effects.
In summary, these data highlight the potentially potent
interactions between HLA class I alleles to mediate HIV-1 disease
control. Even CD8+ T cell responses which are independently
associated with strong viraemic suppression and sustained
immunological control can be improved upon by the co-
expression of certain other favourable HLA class I molecules.
This finding underscores the potential benefit of harnessing co-
operative effects of multiple CD8+ T cell responses in the
development of CD8+ T cell vaccines.
Materials and Methods
Ethics statement
Ethics approval was given by University of KwaZulu-Natal
Review Board and the Massachusetts General Hospital Review
Board (Durban cohort), the Office of Human Research Admin-
istration, Harvard School of Public Health and the Health
Research Development Committee, Botswana Ministry of Health
(Gaborone cohort), and the University of the Free State Ethics
Committee (Durban and Kimberley cohorts). All subjects provided
written informed consent.
Recruitment and characterization of patients
We recruited 2031 HAART-naı ¨ve, southern African adult
subjects with chronic C-clade HIV-1 infection via four cohorts
(Table 1): (i) Durban, South Africa [9,12]; (ii) the Gaborone
region, Botswana [22]; (iii) Bloemfontein, South Africa [23]; (iv)
Kimberley, South Africa [7]. The exact timing of infection in each
individual was not known, but all these subjects were either
presenting with clinical features of HIV infection, or diagnosed by
routine screening in pregnancy – in both cases, in keeping with
chronic infection. Viral loads (VL) were obtained for 1873 subjects
using the Roche amplicor 1.5 assay and CD4+ T cell counts were
determined for 1871 subjects using flow cytometry. All subjects
had either a viral load or a CD4+ count available for analysis; the
majority (84%) had both. Although a single measurement of VL
and CD4+ T cell count for each individual is a limited ‘snap-shot’
Co-Operation between HLA Alleles in HIV-1
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disease outcome/time to AIDS.
HLA typing was performed from genomic DNA by sequence-
based typing. We collapsed all HLA data to two-digit HLA-types,
with three exceptions in which the four-digit type is most likely to
be critical to disease outcome: HLA-A*68:xx [12,24], HLA-
B*15:xx [12,25], and HLA-B*58:xx [5,12,26]. An HLA imputa-
tion tool was used to infer those alleles not collapsed if they were
only typed to two-digit level for any individual [27]. Data were
removed for 75 subjects in whom the four-digit type for HLA-
A*68:xx, HLA-B*15:xx or HLA-B*58:xx could not be determined.
Gag population sequences (p17+p24) were generated from
genomic DNA for 1256 individuals, as previously described [9,23].
Univariate analysis of impact of HLA Class I alleles on HIV-
1 disease control
We undertook a univariate analysis to assess the impact of
individual HLA alleles on disease control. Such a scan has not
always been applied in previous studies that have examined HLA
associations with HIV viral setpoint or absolute CD4+ T cell
count. As such, the contributions of HLA-A and HLA-Cw alleles
that often have less impact than HLA-B have tended to be
obscured [5,7]. Disease control was defined as previously, using
continuous-valued data (absolute CD4+ T cell count and absolute
viral load) and discrete targets (‘controller’ defined as CD4+ T cell
count .250 cells/mm
3; viral load #2000 RNA copies/ml plasma)
[7]. The univariate analysis was performed using an LRT test with
linear or logistic regression for, respectively, continuous-valued
and discrete targets (for example, CD4+ T cell count is real-
valued, whereas ‘controller’ was the binary, thresholded version of
CD4+ T cell count). We evaluated only HLA Class I alleles
occurring at a phenotypic frequency of $0.5%, and used False
Detection Rate (FDR) q,0.05 (5% false positive) or q,0.2 (20%
false positive) [13].
Multivariate analysis of impact of pairs of HLA Class I
alleles on HIV-1 disease control
To identify any two HLA Class I alleles with co-operative
additive effects on disease control, we used previously published
methodology [7]. As described in the introduction, we used the
term ‘co-operative additive’ to describe interplay between two
alleles that is more than a simple additive effect. Briefly, each HLA
combination was tested to see whether an additive model for two
alleles together performed better in predicting disease outcome
than a model that did not allow both alleles to interact. In contrast
to previous analysis [7], we here generalized the test by removing
the restriction that correlations need to be in the ‘direction of
control’, allowing for detection of combinations of ‘beneficial’ and
‘hazardous’ alleles, or two ‘hazardous’ alleles. Note that P-values
were computed for our test in a non-parametric way - using
permutations. The test statistic for an HLA pair was the difference
in log likelihood between these two models after fitting each by
maximum likelihood. P-values were obtained by 50 K permuta-
tions of one HLA allele in the test [7].
As previously, correcting the analysis for cohort origin using
cohort covariates was highly statistically significant [7], but richer
lineage-correction using a linear mixed model (with a phylogenetic
tree-based variance component using Gag sequences) provided no
further benefit; therefore, cohort covariates alone were added to
the analysis. In all paired analyses, we set two criteria for inclusion
of a pair of alleles in the analysis (i) alleles must be expressed
together in at least five subjects, and (ii) alleles must occur
independently of one another in at least five subjects (thereby
removing any pairs in near or complete linkage). The value five
was chosen based on other similar work (e.g. Microsoft PhyloD,
which routinely uses a ‘min count’ filter for the minimum number
of times an HLA allele must appear [28,29]). Because this filtering
step does not consider VL or CD4+ T cell count values, it is a
statistically valid approach, and is conservative in that it can only
cause us to miss real associations, not to detect false associations
spuriously (regardless of the actual filtering threshold used).
Specifically, this filtering threshold was not manipulated in
response to the data (we only ever used this one threshold). Such
‘min count’ thresholds are widely used in similar contexts – e.g. all
genome-wide association studies where mean allele frequency and
Hardy-Weinberg equilibrium thresholds are employed as a
preprocessing step (for example, see [30]).
Statistical tests
Linkage disequilibrium between HLA class I alleles was
computed using Fisher’s Exact Test using the on-line tool at the
Los Alamos HLA molecular immunology database: http://www.
hiv.lanl.gov/content/immunology/hla/hla_linkage.html. This
method reports significant linkage following correction for the
number of tests performed (in this case, threshold for significance is
p,1.9E-05).
Statistical correction for multiple comparisons was performed
using a False Discovery Rate (FDR) with thresholds of q,0.05
(5% FDR) or q,0.2 (20% FDR) [31].
Methods to identify correlation between breadth of
epitope targeting and disease control
In order to investigate any relationship between HIV-1 disease
control (mediated by any pair of HLA alleles) and breadth of
CD8+ T cell responses, we used IFN-g ELISpot data for 1010
South African subjects tested against a panel of 410 C-clade
overlapping peptides (OLPs) spanning the entire HIV-1 proteome,
as previously described [17,32]. We first assigned likely HLA allele
restriction(s) to each OLP using stepwise Fisher’s Exact Test (FET)
to control for linkage disequilibrium. In each iteration, the most
significantly associated HLA allele was determined using FET,
then all individuals who expressed that allele were removed and
the next most significant allele (with corresponding p-value) was
identified. All alleles associated with the OLP at q,0.2 [33] were
considered restricting alleles. For each pair of alleles, we computed
a ‘sharing score’ as a means of quantifying the breadth of unique
epitopes targeted by any given HLA pair. This sharing score was
calculated as the number of shared OLPs divided by the number
of unique OLPs targeted by the pair. Thus a higher sharing score
indicates less total breadth of epitope coverage across the
proteome.
For each pair of alleles, this sharing score was correlated with
the p-value from the additive pairs analysis using a Pearson
correlation. We confirmed the analytically-computed P-values
yielded by Pearson by using a permutation test with 1000
permutations, and the P-values from both approaches were in
agreement.
Note that there is no obvious effect size obtainable for the co-
operative additive test, and even if there were it would be possible
to have large effects for pairs which were not statistically
significant. For these two reasons, we chose to measure correlation
with the p-value. Based on this approach, a larger sharing score
(indicative of wider OLP targeting) correlating negatively with the
p-value for an additive effect (where a smaller p value is indicative
of a stronger co-operative additive effect between alleles) points to
a relationship between breadth of coverage and two alleles acting
co-operatively toward immune control.
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